Resonance Health Ltd · ASX:RHT
Resonance Health — PAC Partners Healthcare Conference 2022
17 slides from Resonance Health's conference presentation, Apr 6, 2022
Slide 1: ASX Announcement – Investor Presentation
ASX Announcement – 6 April 2022 Investor Presentation For personal use only Resonance Health Ltd (ASX: RHT) (“Resonance Health” or the “Company”) attaches the investor presentation, which will be presented at the upcoming PAC Partners Healthcare Conference, featuring leading and emerging ASX-listed
Slide 2: Investor Presentation April 2022
INVESTOR PRESENTATION APRIL 2022 For personal use only
Slide 3: Recognised global leader in medical imaging analysis
2 APRIL 2022 INVESTOR PRESENTATION For personal use only Recognised global leader in providing medical imaging analysis devices + services to clinicians and researchers, to help improve and extend the lives of people suffering from chronic diseases
Slide 4: Investment Highlights
3 APRIL 2022 INVESTOR PRESENTATION INVESTMENT HIGHLIGHTS For personal use only • Global leader in MRI iron + fat calculation • Regulatory-cleared, core-analysis devices + services • Robust patent-protected devices, products + IP portfolio • Addressable diseases have massive human + economic conseque
Slide 5: Regulatory Cleared MRI Analysis Products & Services
4 APRIL 2022 INVESTOR PRESENTATION REGULATORY CLEARED MRI ANALYSIS PRODUCTS & SERVICES For personal use only Customer Analysis Reports Completed (Diagnostic and Clinical Trials) • MRI image analysis + secure report 8,000 delivery services, providing reliable, 7,000 6,000 standardised, diagnostic inf
Slide 6: Products & Services
5 APRIL 2022 INVESTOR PRESENTATION PRODUCTS & SERVICES For personal use only DIAGNOSTIC ANALYSIS & REPORTING CLINICAL TRIAL SERVICES § Quantitative analysis + reporting of organ iron § Comprehensive services for pharma companies + fat delivered to treating clinicians undertaking Phase II, III + IV c
Slide 7: Key Disease Markets We Address: Iron Overload Diseases
6 APRIL 2022 INVESTOR PRESENTATION KEY DISEASE MARKETS WE ADDRESS For personal use only IRON OVERLOAD DISEASES Global Haemoglobin Disorder Prevalence § Incurable, life-long, inherited diseases that drastically affect quality and duration of life including thalassaemia, sickle-cell anaemia, + haemoch
Slide 8: Key Disease Markets We Address: NAFLD
7 APRIL 2022 INVESTOR PRESENTATION KEY DISEASE MARKETS WE ADDRESS For personal use only NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) Global NAFLD and Cardiovascular Disease Prevalence § Build-up of excess fat in liver cells, causes liver damage + leads to NASH (non-alcoholic steatohepatitis), cirrhosi
Slide 9: Products & Services – Core Lab Services
8 APRIL 2022 INVESTOR PRESENTATION PRODUCTS & SERVICES – CORE LAB SERVICES For personal use only § Software-assisted MRI iron and fat quantification devices + services § Quality controlled core-lab services by trained engineers + physicists § Non-invasive, accurate, regulatory cleared medical device
Slide 10: Products & Services – Artificial Intelligence
9 APRIL 2022 INVESTOR PRESENTATION PRODUCTS & SERVICES – ARTIFICIAL INTELLIGENCE For personal use only § 3 x regulatory cleared AI devices § Trained + validated against proven core-lab devices § Highly scalable, rapid turnaround time, + low delivery cost § LiverSmart CPT codes confirmed – on pathway
Slide 11: Revenue Growth Pathways
10 APRIL 2022 INVESTOR PRESENTATION REVENUE GROWTH PATHWAYS For personal use only Grow patient diagnostic service volumes Disease Prevalence & Current Client Markets § Extensive + growing disease prevalence § Growing global patient accessibility to MRI § Disease treatments becoming more affordable §
Slide 12: Device Enhancements & Development
11 APRIL 2022 INVESTOR PRESENTATION DEVICE ENHANCEMENTS & DEVELOPMENT For personal use only § Commitment to ongoing enhancement of existing devices + services § Objective is to ensure customer retention + drive new market penetration § Market-led development of new imaging-based devices + services C
Slide 13: Operating Performance & Cash Balance
12 APRIL 2022 INVESTOR PRESENTATION OPERATING PERFORMANCE & CASH BALANCE For personal use only § Consistent revenue evidences the H1 FY2022 FY2021 FY2020 engrained market position of devices Operating Revenue $1.88M $3.78M $3.67M § H1 FY22 EBITDA reflects commitment Operating EBITDA (ex share-based
Slide 14: Our Strengths & Opportunities
13 APRIL 2022 INVESTOR PRESENTATION OUR STRENGTHS & OPPORTUNITIES For personal use only STRENGTHS OPPORTUNITIES § Gold standard reg-cleared medical § Large, growing, underserviced, devices and services accessible diagnostics markets § Globally-recognised technical § Iron overload + fatty liver disea
Slide 15: Corporate Information
14 APRIL 2022 INVESTOR PRESENTATION CORPORATE INFORMATION For personal use only Shareholder Information Share Price & Volume History ASX Code: RHT Close Volume $0.300 50.0M Ordinary shares on Issue: 461.1M $0.250 45.0M 40.0M 35.0M $0.200 Market Cap (at SP $0.135) $62.2M 30.0M $0.150 25.0M Enterprise
Slide 16: Board & Senior Executives
15 APRIL 2022 INVESTOR PRESENTATION BOARD & SENIOR EXECUTIVES For personal use only Dr Martin Blake Non-Exec Chairman Practicing radiologist and nuclear medicine specialist Previously Chair of Perth Radiological Clinic from 2009-21 Graduated from the University of Melbourne – Melbourne Business Scho
Slide 17: Disclaimer
16 APRIL 2022 INVESTOR PRESENTATION DISCLAIMER For personal use only This presentation has been prepared by Resonance Health Ltd (“Resonance Health” or “Company”) and may contain forward-looking statements that are based on current expectations and beliefs and are subject to numerous factors and unc
Resonance Health — PAC Partners Healthcare Conference 2022 on 6ix